Regenative Labs specializes in the development and provision of high-quality human tissue allografts, particularly focusing on Wharton's jelly and dehydrated amniotic membrane products. Their proprietary offerings, such as CryoText™, SecreText™, ProText™, and AmnioText™, are designed to replace or supplement damaged connective tissues, providing effective and minimally invasive treatment options for patients. The company emphasizes the importance of maintaining the original structural characteristics of the tissue during processing, ensuring that their products perform the same basic functions in recipients as they do in donors. This commitment to quality is further supported by their adherence to FDA regulations regarding minimal manipulation and homologous use of human cells and tissues.

In addition to product development, Regenative Labs is dedicated to advancing the science of regenerative medicine through partnerships with various organizations and a focus on data collection and analysis. By gathering and evaluating patient outcome data, they aim to enhance the predictability of treatment results and support clinicians in making informed decisions. Their research initiatives are designed to explore new applications for their allografts, ultimately contributing to improved patient care and quality of life. Through these efforts, Regenative Labs seeks to establish itself as a leader in the field of regenerative medicine, fostering a collaborative environment for clinicians and researchers alike.

United States

Regenative Labs strives to process the highest quality human tissue allografts available in accordance with FDA and AATB requirements. Regenerative Medicine is a discipline that uses nature’s chemistry and biology to help the body repair itself.

Regenative Labs

Company Details